SI2289490T1 - Nabiti lipoproteinski kompleksi in njihove uporabe - Google Patents

Nabiti lipoproteinski kompleksi in njihove uporabe

Info

Publication number
SI2289490T1
SI2289490T1 SI200631830T SI200631830T SI2289490T1 SI 2289490 T1 SI2289490 T1 SI 2289490T1 SI 200631830 T SI200631830 T SI 200631830T SI 200631830 T SI200631830 T SI 200631830T SI 2289490 T1 SI2289490 T1 SI 2289490T1
Authority
SI
Slovenia
Prior art keywords
lipoprotein complexes
charged lipoprotein
complexes
charged
impart
Prior art date
Application number
SI200631830T
Other languages
English (en)
Slovenian (sl)
Inventor
Jean-Louis H. Dasseux
Original Assignee
Cerenis Therapeutics Holding Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36659702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2289490(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cerenis Therapeutics Holding Sa filed Critical Cerenis Therapeutics Holding Sa
Publication of SI2289490T1 publication Critical patent/SI2289490T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1275—Lipoproteins or protein-free species thereof, e.g. chylomicrons; Artificial high-density lipoproteins [HDL], low-density lipoproteins [LDL] or very-low-density lipoproteins [VLDL]; Precursors thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
SI200631830T 2005-03-24 2006-03-23 Nabiti lipoproteinski kompleksi in njihove uporabe SI2289490T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66518005P 2005-03-24 2005-03-24
EP10010660.8A EP2289490B1 (en) 2005-03-24 2006-03-23 Charged lipoprotein complexes and their uses

Publications (1)

Publication Number Publication Date
SI2289490T1 true SI2289490T1 (sl) 2014-11-28

Family

ID=36659702

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200631830T SI2289490T1 (sl) 2005-03-24 2006-03-23 Nabiti lipoproteinski kompleksi in njihove uporabe
SI200631327T SI1871341T1 (sl) 2005-03-24 2006-03-23 Nabiti lipoproteinski kompleksi in njihove uporabe

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200631327T SI1871341T1 (sl) 2005-03-24 2006-03-23 Nabiti lipoproteinski kompleksi in njihove uporabe

Country Status (19)

Country Link
US (4) US8206750B2 (enExample)
EP (3) EP2289490B1 (enExample)
JP (2) JP5317691B2 (enExample)
KR (4) KR20160077225A (enExample)
CN (2) CN103182069B (enExample)
AT (1) ATE547094T1 (enExample)
AU (1) AU2006226045B2 (enExample)
BR (1) BRPI0607728A2 (enExample)
CA (1) CA2602024C (enExample)
CY (2) CY1112783T1 (enExample)
DK (2) DK1871341T3 (enExample)
ES (2) ES2382958T3 (enExample)
IL (3) IL186169A (enExample)
MX (1) MX2007011851A (enExample)
NZ (2) NZ582888A (enExample)
PL (2) PL1871341T3 (enExample)
PT (2) PT1871341E (enExample)
SI (2) SI2289490T1 (enExample)
WO (1) WO2006100567A1 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
US20060275356A1 (en) * 2005-05-25 2006-12-07 Burgess James W Pharmaceutical compositions for treating or preventing coronary artery disease
ES2402823T3 (es) * 2006-06-01 2013-05-09 Institut De Cardiologie De Montreal Compuesto para uso en el tratamiento de estenosis valvular
US7985728B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US7985727B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Apo A-I mimetic peptides and methods of treatment
US8101565B2 (en) * 2007-09-20 2012-01-24 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US9173890B2 (en) * 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US8044021B2 (en) 2007-09-20 2011-10-25 Abbott Cardiovascular Systems Inc. Sustained release of apo A-I mimetic peptides and methods of treatment
CA2780482A1 (en) 2008-11-17 2010-05-10 Anil K. Sood Hdl particles for delivery of nucleic acids
SMT201700203T1 (it) 2009-02-16 2017-05-08 Cerenis Therapeutics Holding Sa Mimetici di apolipoproteina a-i
EP2676659A1 (en) * 2009-07-16 2013-12-25 INSERM (Institut National de la Santé et de la Recherche Médicale) HDL comprising a therapeutic agent and use in therapy
US12419839B2 (en) 2009-10-09 2025-09-23 Signablok, Inc. Methods and compositions for targeted delivery of protein fragments
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
US10525152B2 (en) * 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
US20110152112A1 (en) * 2009-12-23 2011-06-23 Artery Therapeutics, Inc. Diagnosis and treatment of reverse cholesterol transport deficiency-related diseases
US20130197226A1 (en) * 2010-07-28 2013-08-01 Jean-Claude Tardif Pharmaceutical compositions for the treatment of left ventricular diastolic dysfunction comprising an apolipoprotein peptide/phospholipid complex
AR082644A1 (es) 2010-08-30 2012-12-19 Hoffmann La Roche Tetranectina-apolipoproteina a-i, particulas lipidicas que la contiene y utilizacion de la misma relacionado con el metabolismo de los lipidos y las enfermedades cardiovasculares
AU2015271986B2 (en) * 2011-02-07 2018-02-22 Cerenis Therapeutics Holding Sa Lipoprotein complexes and manufacturing and uses thereof
HUE042314T2 (hu) 2011-02-07 2019-06-28 Cerenis Therapeutics Holding Sa Lipoprotein komplexek és azok gyártása és alkalmazásai
US20140171365A1 (en) * 2011-03-25 2014-06-19 The Trustees Of Columbia University In The City Of New York Pegylated human hdl particle and process for production thereof
CA2838070A1 (en) * 2011-08-25 2013-02-28 F. Hoffmann-La Roche Ag Shortened tetranectin-apolipoprotein a-i fusion protein, a lipid particle containing it, and uses thereof
US20160018413A1 (en) * 2013-03-14 2016-01-21 The Board Of Trustees Of The Leland Stanford Junior University Methods of Prognosing Preeclampsia
US9708354B2 (en) 2013-03-15 2017-07-18 Cerenis Therapeutics Holding Sa Methods for the synthesis of sphingomyelins and dihydrosphingomyelins
JP6438417B2 (ja) 2013-03-15 2018-12-12 セレニス セラピューティクス ホールディング エスアー スフィンゴミエリンおよびジヒドロスフィンゴミエリンの合成のための方法
EP2853259A1 (en) * 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
BR112016025470A2 (pt) 2014-05-02 2017-08-15 Cerenis Therapeutics Holding S A ?hdl terapêutico?
US9763892B2 (en) 2015-06-01 2017-09-19 Autotelic Llc Immediate release phospholipid-coated therapeutic agent nanoparticles and related methods
US20170165200A1 (en) * 2015-11-20 2017-06-15 University Of North Texas Health Science Center Composition of lipid-based nanoparticles for small molecules and macromolecules
WO2019030574A1 (en) * 2017-08-10 2019-02-14 Cerenis Therapeutics Holding Cargomers
WO2019030575A1 (en) * 2017-08-10 2019-02-14 Cerenis Therapeutics Holding APOMÈRES
CN110151972A (zh) * 2018-02-11 2019-08-23 中国中医科学院中医基础理论研究所 基于多肽的重组高密度脂蛋白前体及其制备方法与应用
US12220462B1 (en) 2018-02-13 2025-02-11 Abionyx Pharma Sa Complexes for delivery of cyclic dinucleotides
DE202019003092U1 (de) * 2019-07-24 2020-01-17 Ruth-Maria Korth Test zur Bestimmung von Proteophospholipiden und FIDA-Formeln zur Bestimmung von Schutzfaktoren , die mit Substraten auszugleichen sind
IL297046A (en) 2020-04-16 2022-12-01 Abionyx Pharma Sa Treatment of kidney disease using cer-001
CN115427064A (zh) 2020-04-16 2022-12-02 阿比奥尼克斯制药公司 使用基于脂质结合蛋白的复合物治疗急性病况的方法
EP4221686A2 (en) 2020-10-01 2023-08-09 Abionyx Pharma SA Compositions comprising lipid binding protein-based complexes for use for treating eye diseases
JP2024514154A (ja) 2021-04-15 2024-03-28 アビオニクス ファーマ エスエー 臓器保存溶液における脂質結合タンパク質ベースの複合体の使用
KR102531293B1 (ko) * 2021-12-06 2023-05-16 (주) 멥스젠 신규한 재구축 고밀도 지단백 나노입자
CA3247588A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa METHODS FOR TREATING LEUKOCYTOSIS, ENDOTHELIAL DYSFUNCTION AND CARDITIS USING LIPID-BINDING PROTEIN COMPLEXES
AU2023250345A1 (en) 2022-04-06 2024-11-14 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
AU2023284357A1 (en) 2022-06-10 2025-01-23 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein-based complexes
WO2023237927A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes
IL322074A (en) 2023-01-13 2025-09-01 Abionyx Pharma Sa Treatment using a lipid-binding protein molecule
WO2025093929A1 (en) 2023-10-31 2025-05-08 Abionyx Pharma Sa Lipid binding protein molecule therapy

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5052123A (enExample) * 1973-01-18 1975-05-09
US4466958A (en) * 1981-03-18 1984-08-21 Morrison L M Food supplement
JPS59164553A (ja) * 1983-03-08 1984-09-17 Fuji Photo Film Co Ltd カラ−写真感光材料
DE3417696A1 (de) * 1984-05-12 1985-11-14 Robert Bosch Gmbh, 7000 Stuttgart Vorrichtung zum volumetrischen abmessen und abfuellen von fluessigkeitsmengen
US5128318A (en) * 1987-05-20 1992-07-07 The Rogosin Institute Reconstituted HDL particles and uses thereof
GB8712540D0 (en) 1987-05-28 1987-07-01 Ucb Sa Expression of human proapolipoprotein a-i
US5231090A (en) * 1990-07-30 1993-07-27 University Of Miami Treatment for hypercholesterolemia
US5220043A (en) 1991-03-21 1993-06-15 Ohio University Synthesis of D-erythro-sphingomyelins
SE9103701D0 (sv) 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
WO1995008986A1 (en) 1993-09-27 1995-04-06 Smithkline Beecham Corporation Camptothecin formulations
US5746223A (en) * 1996-10-11 1998-05-05 Williams; Kevin Jon Method of forcing the reverse transport of cholesterol from a body part to the liver while avoiding harmful disruptions of hepatic cholesterol homeostasis
US5840688A (en) 1994-03-22 1998-11-24 Research Corporation Technologies, Inc. Eating suppressant peptides
US5932536A (en) 1994-06-14 1999-08-03 The Rockefeller University Compositions for neutralization of lipopolysaccharides
US5948756A (en) * 1995-08-31 1999-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Therapeutic lipoprotein compositions
IL120005A (en) * 1997-01-14 2000-08-31 Ramot University Authority Of Pharmaceutical compositions for the treatment of the eye
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6287590B1 (en) 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
US6017882A (en) * 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
GB9919713D0 (en) 1999-08-19 1999-10-20 Queen Mary & Westfield College New medical use of high density lipoprotein
US6514523B1 (en) * 2000-02-14 2003-02-04 Ottawa Heart Institute Research Corporation Carrier particles for drug delivery and process for preparation
CA2455170A1 (en) 2000-07-31 2002-02-07 Ottawa Heart Institute Research Corporation Charged phospholipid compositions and methods for their use
US7144862B2 (en) 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7148197B2 (en) 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7217785B2 (en) 2001-05-09 2007-05-15 The Regents Of The University Of California Cysteine-containing peptides having antioxidant properties
AU2002340825B2 (en) 2001-08-20 2007-07-05 Csl Behring Ag HDL for the treatment of stroke and other ischemic conditions
AUPR798901A0 (en) 2001-09-28 2001-10-25 Medvet Science Pty. Ltd. Spheroidal hdl particles with a defined phospholipid composition
MXPA04002848A (es) 2001-09-28 2005-06-06 Esperion Therapeutics Inc Prevencion y tratamiento de restenosis por administracion local de medicamento.
US7223726B2 (en) 2002-01-14 2007-05-29 The Regents Of The University Of California Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
FR2836043B1 (fr) 2002-02-15 2004-06-04 Inst Nat Sante Rech Med Vesicules lipidiques, preparation et utilisations
AU2003239489A1 (en) * 2002-05-17 2003-12-02 Esperion Therapeutics, Inc. Method of treating dyslipidemic disorders
NZ537006A (en) * 2002-05-17 2008-01-31 Esperion Therapeutics Inc The use of apolipoprotein A-I Milano, for the manufacture ofa composition for treating preventing or reducing ischemic reperfusion injury in a tissue or organ
CA2494098A1 (en) * 2002-07-30 2004-02-05 Esperion Therapeutics, Inc. Methods of using non-human animal apoliprotein a-i protein
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
ES2402823T3 (es) * 2006-06-01 2013-05-09 Institut De Cardiologie De Montreal Compuesto para uso en el tratamiento de estenosis valvular
HUE042314T2 (hu) 2011-02-07 2019-06-28 Cerenis Therapeutics Holding Sa Lipoprotein komplexek és azok gyártása és alkalmazásai

Also Published As

Publication number Publication date
IL186169A (en) 2012-06-28
US20120245328A1 (en) 2012-09-27
KR101769191B1 (ko) 2017-08-30
JP5542166B2 (ja) 2014-07-09
WO2006100567B1 (en) 2006-11-30
KR20140088616A (ko) 2014-07-10
KR101475419B1 (ko) 2014-12-22
DK2289490T3 (da) 2014-10-13
CN103182069B (zh) 2016-09-07
US8206750B2 (en) 2012-06-26
DK1871341T3 (da) 2012-06-18
PT2289490E (pt) 2014-10-13
KR20160077225A (ko) 2016-07-01
US11801282B2 (en) 2023-10-31
CA2602024C (en) 2014-10-14
JP2012121928A (ja) 2012-06-28
US20170182121A1 (en) 2017-06-29
KR20080002861A (ko) 2008-01-04
ES2509216T3 (es) 2014-10-17
EP2327396A3 (en) 2012-01-18
HK1156840A1 (en) 2012-06-22
HK1115823A1 (en) 2008-12-12
CY1115613T1 (el) 2017-01-04
CN103182069A (zh) 2013-07-03
US20060217312A1 (en) 2006-09-28
US20140206600A1 (en) 2014-07-24
EP2289490A1 (en) 2011-03-02
PL2289490T3 (pl) 2015-02-27
IL186245A0 (en) 2008-01-20
CY1112783T1 (el) 2016-02-10
IL219721A0 (en) 2012-06-28
US9567388B2 (en) 2017-02-14
PT1871341E (pt) 2012-06-01
NZ582888A (en) 2012-04-27
CA2602024A1 (en) 2006-09-28
JP2008534487A (ja) 2008-08-28
ATE547094T1 (de) 2012-03-15
IL186169A0 (en) 2008-01-20
IL219721A (en) 2016-04-21
CN101170994A (zh) 2008-04-30
WO2006100567A1 (en) 2006-09-28
NZ562346A (en) 2010-03-26
EP1871341A1 (en) 2008-01-02
CN101170994B (zh) 2013-01-02
KR20180026548A (ko) 2018-03-12
BRPI0607728A2 (pt) 2009-10-06
EP1871341B8 (en) 2012-04-11
AU2006226045B2 (en) 2012-01-19
EP2289490B1 (en) 2014-07-23
SI1871341T1 (sl) 2012-06-29
US8617615B2 (en) 2013-12-31
ES2382958T3 (es) 2012-06-14
PL1871341T3 (pl) 2012-07-31
EP2327396A2 (en) 2011-06-01
EP1871341B1 (en) 2012-02-29
AU2006226045A1 (en) 2006-09-28
MX2007011851A (es) 2008-02-22
JP5317691B2 (ja) 2013-10-16

Similar Documents

Publication Publication Date Title
IL186169A0 (en) Charged lipoprotein complexes and their uses
PH12014502397B1 (en) Pesticidal compositions and processes related thereto
ZA200706010B (en) 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-hetero-ayryl-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic and/or immunostimulant activity
MX355431B (es) Composiciones plaguicidas y procesos relacionados con dichas composiciones.
CR9672A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores
SI1888595T1 (sl) Spojine spiro oksindola in uporaba le teh kot terapevtskih agensov
IL186615A0 (en) Spiroheterocylic compounds and their uses as therapeutic agents
PH12013502686A1 (en) Pesticidal compositions and processes related thereto
MX2015008072A (es) Composiciones plaguicidas y los procedimientos relacionados con las mismas.
IL191057A0 (en) Novel 2-amino-heterocycles useful in the treatment of abeta-related pathologies
PH12015501394A1 (en) Pesticidal compositions and processes related thereto
WO2009154463A3 (en) Butyrate as a medicament to improve visceral perception in humans
MY137950A (en) Surface-modified precipitated silicas
GB0423927D0 (en) The treatment of IBD
UA68150U (en) Valiusha', decorative candle
AU303867S (en) Left boot
AU4839P (en) Co-op 33 Malus domestica
AU5423P (en) Co-op 39 Malus domestica
HK1149712A (en) Combination therapy 238
AU303865S (en) Left boot
UA84625C2 (en) Ethylhydroxyphosphonylmethyltetrapropoxycalix[4]arene as amino acids complexing agent
AU316107S (en) Blower pulleys
AU310567S (en) Gear knob
AU302366S (en) Safety change belt
AU318613S (en) Seat